|
Rosemarie Truman
Rosemarie Truman is an entrepreneur, startup catalyst, impact investor and formerly, a corporate executive. Rosemarie is the Founder and CEO of the Center for Advancing Innovation (CAI), a 501c3 non-profit with a mission to identify breakthrough inventions and maximize their commercial potential. She is also the CEO and Co-Founder of Ignite Social Impact, the first crowd-equity platform for social impact investing in “tech for good.” With over 25 years of experience in entrepreneurship, executive leadership, and philanthropy, Rosemarie’s specialty is investment strategy, having led growth strategies for 50 of the global Fortune 100 companies in over 15 countries.
As CAI’s leader, Rosemarie pioneered a first-of-a-kind, award-winning, disruptive innovation platform. Orchestrating 9 innovative challenge-accelerator models CAI has been the catalyst for the launch of 300+ companies, 3000+ entrepreneurs, and 120+ partnerships across federal labs, universities and hospitals. CAI has received several awards for example, the Health and Human Services Secretary’s Pick Innovation Award. In addition, CAI has had nine Obama White House mentions such as #6 in the top 10 initiatives that happened during the administration in innovation. Prior to launching her own firm, Rosemarie spearheaded IBM’s Innovation strategy practice globally and was awarded IBM’s most laudable honor, the Golden Circle Award. In addition, she has also held leadership roles at Booz Allen Hamilton, Oracle, PRTM, and Marsh & McLennan, where she served as VP of global strategy. Rosemarie began her career at Goldman Sachs in investment banking, establishing a breakthrough straight through processing platform for the NYSE floor. Read more: https://en.wikipedia.org/wiki/Center_for_Advancing_Innovation |
|
LTC (Ret) Stephen DeLellis, PA-C, MPASLTC (Ret) Steve DeLellis is a Physician Assistant with more than 36 years of experience in Army Special Operations and more than 16 combat deployments in six conflicts. Steve previously served as the Deputy Surgeon for the XVIII Airborne Corps, Chief of Medical Training for the U.S. Army Special Operations Command (USASOC), with oversight of the Joint Special Operations Medical Training Center (JSOMTC), and as the Deputy Command Surgeon for the United States Army Special Operations Command. He has managed the longest continually running TBI surveillance project in the Special Operations community and has co-authored more than a dozen articles on mild traumatic brain injury in Special Operations Forces. Steve is an Army Medical Department Iron Major, a member of the Order of Military Medical Merit and the 2019 United States Army recipient of the Henry M. Jackson Foundation Hero of Military Medicine award. Steve is the principal advisor and founder at Defense Medical Strategies and currently serves as the Executive Director of the Fort Bragg Research Institute.
Read more: https://pahx.org/assistants/delellis-stephen/ |
|
Dr. Jack Lewin, MDPrior to his current position as Chairman of the National Coalition on Health Care (NCHC) in Washington, D.C., and with Lewin and Associates, Dr. Jack served as President and Chief Executive Officer of the Cardiovascular Research Foundation. Previously, Dr. Lewin was CEO of the American College of Cardiology (ACC) from 2006 through April 2012. The 41,000 member ACC represents over 90% of U.S. cardiologists, 5,000 cardiovascular nurses and clinicians and over 5,000 international members. Prior to his stint at ACC, Lewin was CEO of the 35,000 member California Medical Association for eight years. Previously, he was Hawaii’s Director of Health from 1986-1994, overseeing 6,500 employees, 12 hospitals and a billion-dollar budget. Before that, as a Commissioned Officer in the US Public Health Service, Dr. Lewin was the founder and first Director of the Navajo Nation Department of Health, serving the needs of America’s largest American Indian tribe. In 2011, he was named as one of Modern Healthcare’s 100 Most Influential People in Healthcare. Dr. Lewin received his BA in Biological Sciences from the University of California, Irvine, and his MD from the University of Southern California.
Read more: https://nchc.org/staff-members/jack-lewin-2/ |
|
robert stroud, PHDDr. Robert Stroud is a Professor of Biochemistry and Biophysics at University of California, San Francisco (UCSF), where he studies the molecular mechanisms of certain key biological processes, as well as signal transduction between processes at the level of protein structure, dynamics, and mechanism. He began his studies at Cambridge University in 1961, studying physics and mathematics, where he first began to study X-ray crystallography and protein structures and continued with his PhD work in physics in the laboratory of J.D. Bernal, where Rosalind Franklin had previously discovered the double helical structure of DNA. He was one of the first scientists to decode a crystal structure (of tubercidin). He completed his postdoctoral studies at the California Institute of Technology before becoming an assistant professor at Caltech. In 1976, he joined UCSF's faculty and was one of the founders of their structural biology program. He continues to work towards improving drug design and our understanding of biological molecules. He is part of the National Academy of Sciences, Royal Society of Medicine, and has received numerous honors and awards for his pioneering work in X-ray crystallography, biophysics, and structural biology.
Read more: https://www.pnas.org/content/103/14/5256 |
|
JEFF KARP, PHDDr. Jeff Karp is a Professor of Medicine at Brigham and Women’s Hospital, Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute, and an affiliate faculty at the Broad Institute and at the Harvard-MIT Division of Health Sciences and Technology (where he teaches to HST and MIT-Sloan business school students). His work spans the fields of drug delivery, medical devices, stem cell therapeutics, and tissue adhesives. He He has published >100 peer-reviewed papers (with >16,500 citations), has given >275 national and international invited lectures, and has >100 issued or pending national/international patents. Several technologies developed in his lab have formed the foundation for multiple products on the market and currently under development and for the launch of six companies that have raised over $180 Million in funding including Skintifique (a skincare company), Gecko Biomedical (a tissue adhesive company), Alivio Therapeutics (an inflammation targeting company), Frequency Therapeutics (a regenerative medicine company), Molecular Infusions (a cannabinoid company), and Landsdowne Labs (a child safety company). In addition to his research goals, Karp is dedicated to the career development of next generation bioengineers to work at the forefront of regenerative medicine.
Read more: https://hsci.harvard.edu/people/jeffrey-karp-phd |
|
AGNIESZKA CZECHOWICZ, MD, PHDDr. Agnieszka Czechowicz is an Assistant Professor at Stanford University. She is a pediatric hematologist/oncologist, and sub-focuses on pediatric stem cell transplantation. She also runs a translational research group focusing on understanding hematopoeitic stem cells and how they interact with their microenvironments. Agnieszka completed her residency in Pediatrics at Boston Children's Hospital, and pursued fellowship training at the Dana Farber Cancer Institute and Lucile Packard Children's Hospital. She consulted for Third Rock ventures and incubated numerous companies including Editas, Magenta Therapeutics, and Global Blood Therapeutics, and currently advises GV. She graduated from Stanford University School of Medicine with a MD/PhD in developmental biology in the Medical Scientist Training Program, in record breaking time. She also earned an undergraduate degree with honors from Stanford University, in biological sciences and received the Firestone medal for her outstanding senior thesis. Agnieszka is an author on numerous publications, including a first author on a paper published in the November 2007 issue of Science which shows a possible way to eliminate the toxicity of bone marrow transplantation (BMT), a discovery that could expand the applications of BMT to include cures for most blood diseases, as well as autoimmune diseases like diabetes. She is in the process of translating these discoveries and developing them into new therapies for patients.
Read more: https://profiles.stanford.edu/agnieszka-czechowicz |